雷递网 雷建平 1月25日 Ascentage Pharma(亚盛医疗,股票代码:“AAPG”)昨日在美国纳斯达克上市。亚盛医疗发行价17.25美元,发行732.5万股,募资1.26亿美元。 亚盛医疗开盘价为17.25美元,收盘价为17.38美元,较发行价上涨0.13%;以收盘价计算,公司市值约14.83亿美元。 亚盛医疗已经在港交所上市,截至昨日收盘,公司在港股股价...
1/21,亚盛医药(Ascentage Pharma)计划通过在纳斯达克首次公开募股(IPO)筹集近1.49亿美元,成为今年首家寻求赴美上市的主要中国企业。该癌症药物开发商于2019年在香港上市,此次目标估值为17.5亿美元,拟以每股20.34美元的价格发行730万份美国存托股票(ADS),每份ADS代表四股普通股。 此次募资计划距亚盛医药与武田(Takeda)签...
Ascentage Pharma and Takeda, a multinational pharmaceutical company, have entered into an exclusive option agreement that granted Takeda an exclusive option to enter into an exclusive license agreement for olverembatinib. Once exercised, the Option would allow Takeda to license global rights to deve...
1/21,亚盛医药(Ascentage Pharma)计划通过在纳斯达克首次公开募股(IPO)筹集近1.49亿美元,成为今年首家寻求赴美上市的主要中国企业。该癌症药物开发商于2019年在香港上市,此次目标估值为17.5亿美元,拟以每股20.34美元的价格发行730万份美国存托股票(ADS),每份ADS代表四股普通股。此次募资计划距亚盛医药与武田(Takeda)签订...
Ascentage Pharma raised a total of $239.41M. Who are the investors of Ascentage Pharma? Investors of Ascentage Pharma include Takeda Pharmaceutical, Oriza Holdings, YuanMing Capital, HDY International Investment, Teng Yue Partners and 11 more. Looking for a leg up on competitive, customer and techn...
In June 2024, we entered into an exclusive option agreement with Takeda Pharmaceuticals International AG, or Takeda, where we granted Takeda an exclusive option to take an exclusive license (even as to us and our affiliates) to research, develop, import, export, make, have made, manufacture, ...
Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies such as Take...
Ascentage Pharmahas built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies such as Takeda, AstraZeneca, Merck, Pfizer and Innovent; and research and development relationships with ...
ASCENTAGE-B: Ascentage Pharma Received CDE Clearance for RegistrationalPhase III Studies of APG-2449 for Treatment of Patients with NSCLC Oct 8 07:30 ASCENTAGE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024 Oct 4 21:43 ASCENTAGE-B: INTERIM ...
Takeda-backed Ascentage Pharma sets terms for $170M IPOSA NewsTue, Jan. 21 Ascentage Pharma Group International reports 1H resultsSA NewsFri, Aug. 26, 2022 ASPHF Company Profile Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic he...